Center on Health Equity & Access

Heart failure deaths increasingly occur at home or in hospice, but racial, sex, and regional disparities persist in end-of-life care.

Trump secures new pricing deals with 9 drugmakers, advancing his effort to align US drug costs with Europe and expand direct-to-consumer purchasing.

Limiting health-related social needs screening to lower-income areas would reduce screening burdens; however, this study found a 2-stage screening approach based on geography to be suboptimal.

Reflect on the challenges in health equity, care access, and policy shifts impacting health insurance and clinical research in 2025.

A new study finds patients with unmet social needs like housing or transportation face higher ED and inpatient use and that resolving these needs may reduce utilization.

With ACA subsidies expiring, experts warn coverage losses could worsen access to behavioral health care and emergency department strains.

The past year has seen multiple changes in the HIV space that have long-term effects when it comes to ending the epidemic.

The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.

AHA 2025 highlights included new guidelines and targeted approaches advancing heart failure and cardiovascular care.

Blinatumomab enhances survival in pediatric B-cell ALL, yet homecare challenges hinder its outpatient delivery.

Pediatric atopic dermatitis advances, ruxolitinib safety, IgE insights, and more at the Society for Pediatric Dermatology (SPD) 2025 meeting.

Financial and social barriers hinder access to specialized care and impact treatment outcomes for adolescents and young adults with leukemia.

Cervical cancer screening adherence drops below 10%, highlighting confusion over evolving guidelines and significant disparities in HPV awareness.

Many US patients with diabetes cannot afford their medical care. The authors review the impact of interventions that reduced and/or eliminated diabetes-related costs.

Research at the San Antonio Breast Cancer Conference highlights T-DXd's superior efficacy and safety in HER2+ metastatic breast cancer, especially among diverse populations.

Democrats move to extend ACA subsidies as enrollment closes, leaving consumers uncertain about premiums, coverage, and alternative health options.

The RAISE program provides awareness and shares comprehensive solutions to address the multifaceted reasons for missing and incomplete data across the real-world data continuum.

A panel at the American Society of Hematology highlights the urgent need for genetic diversity in cancer studies, addressing disparities in treatment outcomes across different ancestries.

Public health dental hygienists expand dental care access and oral health education in underserved communities, improving overall health outcomes.

Hereditary ovarian cancer genes occur across diverse populations, supporting inclusive genetic testing.

Polarized dermatoscopes produced higher-quality teledermatology images but at greater cost, raising questions about feasibility and equitable access.

Prerna Mewawalla, MD, discusses innovative strategies to enhance cancer care access, reduce clinician burden, and improve clinical trial diversity in real-world settings.

Guideline-recommended HF therapies do not improve major outcomes in Chagas disease, though sacubitril/valsartan improved NT-proBNP levels, new data show.

With ACA subsidies ending in 2025, Ben Light explains how rising premiums may push individuals toward ICHRAs and reshape employer health coverage strategy.

The guidelines highlight the need for lifelong obesity management, early diagnosis, comorbidity prevention, and patient-centered care.